NCT03681184COMPLETEDanonymous

ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

Sponsor

Source record

Alnylam Pharmaceuticals

Phase

Source record

PHASE3

Modality

AI-normalized

small molecule

Target

AI-normalized

Placebo, Lumasiran

Indication / condition

AI-normalized

Primary Hyperoxaluria Type 1 (PH1)

Intervention

Source record

Placebo, Lumasiran

Related intelligence directories

Indication directory: Primary Hyperoxaluria Type 1 (PH1)Modality directory: small molecule Target directory: Placebo

Source & freshness

Source record

NCT ID

NCT03681184

Original source

ClinicalTrials.gov

Source last updated

Aug 12, 2024

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT03681184

Title

ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

Sponsor

Alnylam Pharmaceuticals

Status

COMPLETED

Phase

PHASE3

Condition raw

Primary Hyperoxaluria Type 1 (PH1)

Condition normalized

Primary Hyperoxaluria Type 1 (PH1)

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Placebo, Lumasiran

Target normalized

Placebo, Lumasiran

Interventions

Placebo, Lumasiran

Public preview

Source record

The purpose of this study is to evaluate the efficacy and safety of lumasiran in children and adults with primary hyperoxaluria type 1 (PH1).

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT03681184

Status

COMPLETED

Phase

PHASE3

Sponsor

Alnylam Pharmaceuticals

Executive brief

Investment-Ready Snapshot

The purpose of this study is to evaluate the efficacy and safety of lumasiran in children and adults with primary hyperoxaluria type 1 (PH1).

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedAug 12, 2024

Internal syncJun 11, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03681184

Indication

Primary Hyperoxaluria Type 1 (PH1)

Modality

small molecule

Target

Placebo, Lumasiran

Intervention

Placebo, Lumasiran

Source record